



Commentary

Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?

Andrea Giacomelli^{a,b,*}, Federico Conti^{a,b}, Stefano Rusconi^{a,b}

^a Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy

^b Luigi Sacco Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Italy



ARTICLE INFO

Article History:

Received 15 May 2020

Accepted 15 May 2020

Available online xxx

The paradigm of antiretroviral therapy shifted in the last few years from the “mantra” of triple therapy to the possibility of using two-drug combination initially as maintenance strategies [1], and in fact as first-line regimens [2]. The possibility of such a shift was allowed by the availability of compounds with a high genetic barrier to resistance as “core agents”, protease inhibitors, and the second-generation integrase inhibitor dolutegravir. This strategy looks at the avoidance of untoward long-term effects related to the exposure of antiretrovirals with regards to nucleos(t)ide reverse transcriptase inhibitors with potential metabolic [3], bone and renal toxicities [4]. Nevertheless, for a relevant percentage of patients, the possibility to switch to regimens composed of fewer drugs is challenged by the presence of archived genotypic mutations in their historical genotype.

In the recent article published in *EBioMedicine*, De Miguel and co-workers assessed the switch to dolutegravir plus lamivudine in patients without previous exposure to integrase inhibitors with and without previously acquired lamivudine resistance [5]. The study addresses a topic that continues to challenge physicians involved in the treatment of people living with HIV. In particular, the possibility of switching patients with a lamivudine containing dual regimen with and without previously archived lamivudine resistance in the historical RNA genotype. The authors selected only patients without a lamivudine resistance detectable at the time of the switch in the proviral DNA by Sanger sequencing. The authors concluded that dolutegravir plus lamivudine was effective in maintaining virological suppression despite the presence of lamivudine resistance mutations in

the historical genotype and the presence of archived mutations assessed by next-generation sequencing.

Some limitations related to the pilot-study design warrant a mention. First, the small study population warrants us to interpret the findings with caution. The probability of virological failure at 48 weeks, which was the primary and endpoint is not a frequent event in patients who switch under virological control. The limited sample size may have influenced the results toward showing no difference between the groups. Second, the convenience sample from patients enrolled in a previous study (GEN-PRO [6]) could have introduced a selection bias by enrolling patients with a good adherence to antiretrovirals and with higher probability of treatment success. Third, the use of proviral DNA to guide clinical decision to change an antiretroviral regimen could be questionable. This strategy may not be feasible for the majority of clinical centers that manage people living with HIV including some high income countries, especially when we consider the use of next-generation sequencing. On one hand, the assumption that a negative detection of resistance at the time of the switch in the proviral DNA correlate with the time of viral suppression before the switch may sound reasonable, but on the other side, it may be questionable due to the possible presence of archived mutations not detected by the test or the fading away of latently infected cells. Nonetheless, the increased sensitivity provided by a next-generation sequencing facilitates more informed decision making to make the therapeutic switch is still a matter of debate. The findings of the present study confirm that there is no difference in virological failure in those with and without lamivudine resistance detected by next-generation sequencing [7].

Data from observational studies suggest that the time of viral suppression before the switch in patients under virological control with previous NRTIs resistance could be one of the most important factors in determining the risk of virological failure [8]. The study by De Miguel et al. underlines that patients with previous lamivudine resistance had a longer duration of viral suppression before the switch compared to those without lamivudine resistance (7.7 years vs 5.3 years) [5]. Thus, the prolonged viral suppression in patients with archived lamivudine resistance could have increased the probability of virological success when compared to those without resistance.

We also have to consider the growing evidence that NRTIs can contribute to treatment success in the presence of previous resistance, in the reverse transcriptase or other enzymes, when combined with a high-genetic-barrier anchor drug. While this effect could be

DOI of original article: <http://dx.doi.org/10.1016/j.ebiom.2020.102779>.

* Corresponding author: Andrea Giacomelli, MD, DIBIC Luigi Sacco, University of Milan, III Infectious Diseases Unit, Luigi Sacco Hospital, Via G.B. Grassi 74, 20157 Milano, Italy, Tel.: +39.02.50319761; Fax: +39.02.50319758.

E-mail addresses: andrea.giacomelli@unimi.it, dott.giacomelli@gmail.com (A. Giacomelli).

<https://doi.org/10.1016/j.ebiom.2020.102820>

2352-3964/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

class- or drug-specific, M184V/I data suggest that the duration of virological suppression has a critical role in decreasing the amount of previously resistant variants below a clinically relevant threshold.

Although these findings are preliminary, after combining them with those coming from observational studies [9, 10] we can suggest the possibility to simplify patients who have archived in their historical genotype lamivudine resistance to dolutegravir plus lamivudine as a maintenance regimen.

Declaration of competing interests

AG was a paid consultant for Mylan. SR received research grants to his Institution from ViiV Healthcare, Gilead Sciences and Janssen, outside the submitted work; he was also a paid consultant for ViiV Healthcare, Gilead Sciences, Merck Sharp and Dohme, Bristol-Myers Squibb, Janssen and Mylan. FC has nothing to declare.

Acknowledgements

The manuscript is dedicated to all patients and health care workers who are fighting globally against SARS-CoV-2 infection.

References

- [1] Ciccullo A, Baldin G, Capetti A, et al. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. *Antivir Ther* 2019;24(1):63–7.
- [2] Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials [published correction appears in *Lancet*. 2018 Nov 28;:]. *Lancet* 2019;393(10,167):143–55.
- [3] Alvarez A, Orden S, Andújar I, Collado-Díaz V, Núñez-Delgado S, Galindo MJ, Estrada V, Apostolova N, Esplugues JV. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. *AIDS* 2017 Aug 24;31(13):1781–95.
- [4] Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO. Tenofovir-associated renal and bone toxicity. *HIV Med* 2009 Sep;10(8):482–7.
- [5] De Miguel, et al., et al. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). *EBioMedicine* 2020 Access from: doi: 10.1016/j.ebiom.2020.102779.
- [6] Domínguez-Domínguez L, Montejano R, Esteban-cantos A, García M, Stella-scariz N, Bisbal O, et al. Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN- PRO). 17th European AIDS Conference; 2019. Poster PE13/2.
- [7] Tzou PL, Ariyaratne P, Varghese V, Lee C, Rakhmanaliev E, Villy C, Yee M, Tan K, Michel G, Pinsky BA, Shafer RW. Comparison of an In Vitro Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing. *J Clin Microbiol* 2018 May 25;56(6).
- [8] Giacomelli A, Lai A, Franzetti M, ARCA collaborative group. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. *Antiviral Res* 2019 Dec;172:104. 635.
- [9] Gagliardini R, Ciccullo A, Borghetti A, ARCA Study Group. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. *Open Forum Infect Dis* 2018 May 15;5(6) ofy113.
- [10] Galizzi N, Poli A, Galli L, et al. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. *Int J Antimicrob Agents* 2020 Mar;55(3):105. 893.